AnaptysBio (ANAB) stock price, revenue, and financials

AnaptysBio market cap is $730.2 m, and annual revenue was $8 m in FY 2019
View Company

$730.2 M

ANAB Mkt cap, 23-Feb-2021
AnaptysBio Net income (Q3, 2020)-23.8 M
AnaptysBio EBIT (Q3, 2020)-24.3 M
AnaptysBio Cash, 30-Sept-2020209.2 M
AnaptysBio EV521.9 M

AnaptysBio Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

10.0m5.0m8.0m

R&D expense

29.4m56.2m99.3m

General and administrative expense

9.3m15.5m16.1m

Operating expense total

38.8m71.7m115.4m

EBIT

(28.8m)(66.7m)(107.4m)

EBIT margin, %

(288%)(1334%)(1343%)

Interest income

1.6m6.7m11.0m

Pre tax profit

(30.1m)(61.8m)(97.5m)

Income tax expense

(192.0k)(152.0k)

Net Income

(30.1m)(61.7m)(97.3m)

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

7.0m5.0m5.0m15.0m

R&D expense

7.9m7.2m6.7m11.8m10.6m17.9m20.6m27.4m29.9m21.0m17.9m19.5m

General and administrative expense

2.1m2.4m2.4m3.9m3.8m4.0m4.1m4.3m3.8m4.3m4.7m4.8m

Operating expense total

10.0m9.6m9.1m15.8m14.4m21.9m24.8m31.7m33.7m25.3m22.6m24.3m

EBIT

(10.0m)(2.6m)(9.1m)(15.8m)(14.4m)(16.9m)(24.8m)(26.7m)(33.7m)(10.3m)(22.6m)(24.3m)

EBIT margin, %

(36%)(338%)(533%)(68%)

Interest expense

1.2m1.3m1.4m3.0m3.0m2.8m

Interest income

449.0k

Pre tax profit

(22.1m)(24.0m)(31.1m)(8.3m)(21.5m)(23.8m)

Income tax expense

(19.0k)(60.0k)(51.0k)

Net Income

(11.4m)(2.7m)(9.1m)(15.1m)(13.6m)(16.0m)(22.1m)(24.0m)(31.0m)(8.3m)(21.5m)(23.8m)

AnaptysBio Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

81.2m113.6m171.0m

Accounts Receivable

Prepaid Expenses

2.7m7.0m3.5m

Current Assets

252.7m434.2m377.7m

PP&E

665.0k1.4m1.6m

Total Assets

329.4m509.0m435.2m

Accounts Payable

2.3m5.4m16.2m

Short-term debt

6.9m7.6m2.2m

Current Liabilities

14.1m21.8m29.5m

Long-term debt

654.0k

Total Debt

6.9m7.6m2.9m

Common Stock

24.0k27.0k27.0k

Additional Paid-in Capital

393.0m633.3m648.7m

Retained Earnings

(85.0m)(146.7m)(244.0m)

Total Equity

307.6m486.4m405.0m

Financial Leverage

1.1 x1 x1.1 x

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

96.8m30.8m26.7m69.5m57.1m293.4m105.9m146.6m182.9m165.3m221.2m209.2m

Accounts Receivable

5.0m5.0m5.0m

Prepaid Expenses

1.7m3.9m3.1m2.2m3.8m4.0m6.1m3.8m3.6m3.6m6.6m7.5m

Current Assets

110.2m115.8m120.3m251.9m271.8m503.0m421.9m431.0m424.6m371.1m384.5m345.8m

PP&E

569.0k543.0k513.0k659.0k1.1m1.3m1.6m1.5m1.7m1.6m1.5m1.6m

Total Assets

131.1m130.4m121.9m314.8m306.0m523.1m494.2m480.1m451.5m424.2m401.7m384.8m

Accounts Payable

2.5m3.7m2.6m2.4m4.4m6.2m9.1m10.9m10.5m8.6m6.3m5.5m

Short-term debt

1.3m3.1m5.0m7.5m7.5m7.5m7.3m5.6m3.9m898.0k925.0k851.0k

Current Liabilities

8.1m10.1m11.2m14.3m16.8m20.9m24.8m30.6m29.7m23.3m20.1m24.5m

Long-term debt

1.3m1.1m883.0k419.0k180.0k33.0k

Total Debt

1.3m3.1m5.0m7.5m7.5m7.5m8.6m6.7m4.8m1.3m1.1m884.0k

Common Stock

20.0k20.0k20.0k24.0k24.0k27.0k27.0k27.0k27.0k27.0k27.0k27.0k

Additional Paid-in Capital

176.5m178.3m179.6m395.4m399.4m629.9m636.7m640.6m644.1m651.7m654.5m657.6m

Retained Earnings

(66.4m)(69.1m)(78.2m)(100.1m)(113.7m)(129.7m)(168.8m)(192.7m)(223.8m)(252.3m)(273.8m)(297.6m)

Total Equity

110.1m109.2m101.4m294.5m285.0m499.7m468.2m448.4m420.9m400.6m381.4m360.2m

Financial Leverage

1.2 x1.2 x1.2 x1.1 x1.1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x

AnaptysBio Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(30.1m)(61.7m)(97.3m)

Depreciation and Amortization

183.0k315.0k514.0k

Accounts Payable

2.2m7.1m14.5m

Cash From Operating Activities

(19.4m)(48.5m)(69.5m)

Purchases of PP&E

(290.0k)(1.1m)(805.0k)

Cash From Investing Activities

(243.1m)(142.5m)131.4m

Short-term Borrowings

(6.9m)(7.5m)

Cash From Financing Activities

292.5m223.4m(4.5m)

Net Change in Cash

30.0m32.4m57.4m

Interest Paid

1.1m1.0m424.0k

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(11.4m)(14.1m)(23.2m)(15.1m)(28.7m)(44.7m)(22.1m)(46.0m)(77.1m)(8.3m)(29.8m)(53.6m)

Depreciation and Amortization

39.0k90.0k136.0k54.0k118.0k209.0k115.0k239.0k374.0k140.0k277.0k415.0k

Accounts Payable

682.0k2.1m1.1m(158.0k)2.1m5.9m5.1m12.7m13.2m(5.2m)(8.5m)(4.4m)

Cash From Operating Activities

(8.1m)(10.7m)(14.6m)(12.5m)(21.4m)(36.2m)(16.1m)(31.6m)(53.7m)(15.1m)(34.7m)(51.7m)

Purchases of PP&E

(85.0k)(153.0k)(166.0k)(232.0k)(536.0k)(857.0k)(180.0k)(421.0k)(701.0k)(87.0k)(170.0k)(258.0k)

Cash From Investing Activities

(27.1m)(89.5m)(90.0m)2.1m(916.0k)23.7m9.7m67.5m127.4m10.8m86.1m90.9m

Short-term Borrowings

(1.2m)(3.1m)(5.0m)(1.9m)(3.7m)(5.6m)(1.4m)(1.4m)(1.4m)

Cash From Financing Activities

80.7m79.8m80.1m(1.4m)(1.9m)224.7m(1.3m)(3.0m)(4.4m)(1.3m)(1.3m)(1.0m)

Net Change in Cash

(20.5m)(24.6m)(11.7m)(24.1m)212.2m(7.7m)33.0m69.3m(5.7m)50.2m38.1m

Interest Paid

278.0k469.0k762.0k297.0k585.0k835.0k172.0k301.0k384.0k4.0k4.0k4.0k

AnaptysBio Ratios

USDQ1, 2017

Financial Leverage

1.2 x

AnaptysBio Employee Rating

3.813 votes
Culture & Values
3.5
Work/Life Balance
3.8
Senior Management
3.2
Salary & Benefits
3.8
Career Opportunities
3.4
Source
View AnaptysBio profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more